Roughly one-fifth of supplemental indications were approved many years after a drug’s initial launch, many of which target populations with high unmet medical needs.
Meng Li, PhD
Advertisement
Articles by Meng Li, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
emtelligent Turns Unstructured Clinical Data Into Actionable Insights
2
Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo
3
Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD
4
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
5